Latest News & Features
Refine Search
Americas
Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process. 20 July 2023
Biotechnology
Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21. 18 July 2023
Generics
Generic drug makers are watching two cases that will determine whether pharmaceutical firms can deduct—rather than capitalise—legal fees for defending against patent infringement suits, say Carina Federico and Anne Li of Crowell & Moring. 18 July 2023
Big Pharma
Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’. 13 July 2023
Big Pharma
Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules. 13 July 2023
Americas
Precedential decision marks blow for medical device maker after earlier win | PTAB criticised for “fundamental legal error” and “narrow definition”. 11 July 2023
Generics
Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug. 11 July 2023
Americas
John Rearick is the latest addition to the firm to strengthen its life sciences practice. 11 July 2023
Americas
Certain problems with the patent opposition process need to be addressed in order to protect patent owners, say Alejandro Luna and Luz Elena Elias of Olivares. 9 July 2023
Americas
Commission says that medical device maker’s arguments have broad implications for antitrust enforcement | Dispute concerns alleged exclusive-dealing and bundling arrangements. 5 July 2023